Upstream Bio (UPB) Stock Analysis & AI Equity Report

Biotechnology USD Explore free reports

Upstream Bio (UPB) overview

Upstream Bio (UPB) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 2.9m and operating profit of USD -160m; the year-end share price was 27.15 USD and market capitalisation was USD 1,473m. Upstream Bio is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Upstream Bio's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 340mFY 2025
Share price27.15 USDFY 2025 year end
RevenueUSD 2.9mFY 2025
Operating profitUSD -160mFY 2025
Net earningsUSD -143mFY 2025
Market capitalisationUSD 1,473mFY 2025 year end

About Upstream Bio

Upstream Bio is a clinical-stage biotechnology company developing treatments for severe inflammatory respiratory diseases. Its lead candidate, verekitug, is a monoclonal antibody designed to block the receptor for thymic stromal lymphopoietin. The company plans to start Phase 3 trials in severe asthma and chronic rhinosinusitis with nasal polyps in 2027, while a Phase 2 COPD trial continues. Patients with these conditions are its intended beneficiaries.

Generate the Upstream Bio report

Upstream Bio is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Upstream Bio and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Upstream Bio

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.